Widely prescribed blood pressure drugs linked to 33% higher kidney risk in type 2 diabetes
A widely prescribed blood pressure drug was associated with a 33% higher risk of serious kidney problems in people with type 2 diabetes, even when they were already taking kidney-protective medications. The surprising finding is prompting researchers to question whether DCCBs are
For individuals living with type 2 diabetes, managing blood pressure is crucial to prevent complications such as kidney disease. The recent finding that a commonly prescribed blood pressure medication, known as dihydropyridine calcium channel blockers (DCCBs), may increase the risk of serious kidney problems by 33% is concerning. This is especially true for those already taking medications to protect their kidneys.
This study highlights the importance of carefully weighing the benefits and risks of blood pressure medications, particularly for individuals with type 2 diabetes. While DCCBs are often prescribed to help manage high blood pressure, the potential kidney risks associated with these medications may outweigh the benefits for some patients. The fact that the increased risk was observed even among individuals taking kidney-protective medications underscores the need for closer monitoring and alternative treatment strategies.
As researchers continue to investigate the link between DCCBs and kidney risk in type 2 diabetes, patients and healthcare providers should be aware of the potential risks and benefits of these medications. What's next to watch is whether further studies will confirm these findings and if alternative blood pressure medications or treatment approaches will be explored to minimize kidney risks for individuals with type 2 diabetes.
Originally reported by sciencedaily.com. WellnessNews adds analysis for health & wellness readers.